114 related articles for article (PubMed ID: 9491826)
1. Hormonal effects of MPV-2213ad, a new selective aromatase inhibitor, in healthy male subjects. A phase I study.
Ahokoski O; Irjala K; Huupponen R; Halonen K; Salminen E; Scheinin H
Br J Clin Pharmacol; 1998 Feb; 45(2):141-6. PubMed ID: 9491826
[TBL] [Abstract][Full Text] [Related]
2. A double-blind study of MPV-2213ad, a novel aromatase inhibitor, in healthy male subjects.
Ahokoski O; Irjala K; Huhtala S; Salminen E; Scheinin H; Huupponen R
Eur J Clin Pharmacol; 1999 Mar; 55(1):27-34. PubMed ID: 10206081
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men.
Ahokoski O; Irjala K; Taalikka M; Manninen P; Halonen K; Kangas L; Salminen E; Huupponen R; Scheinin H
Br J Clin Pharmacol; 2001 Dec; 52(6):702-4. PubMed ID: 11736883
[TBL] [Abstract][Full Text] [Related]
4. Open dose-finding study of a new potent and selective nonsteroidal aromatase inhibitor, CGS 20 267, in healthy male subjects.
Trunet PF; Mueller P; Bhatnagar AS; Dickes I; Monnet G; White G
J Clin Endocrinol Metab; 1993 Aug; 77(2):319-23. PubMed ID: 8345034
[TBL] [Abstract][Full Text] [Related]
5. Acute inhibition of oestrogen biosynthesis does not affect serum leptin levels in young men.
Luukkaa V; Rouru J; Ahokoski O; Scheinin H; Irjala K; Huupponen R
Eur J Endocrinol; 2000 Feb; 142(2):164-9. PubMed ID: 10664525
[TBL] [Abstract][Full Text] [Related]
6. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers.
Yates RA; Dowsett M; Fisher GV; Selen A; Wyld PJ
Br J Cancer; 1996 Feb; 73(4):543-8. PubMed ID: 8595172
[TBL] [Abstract][Full Text] [Related]
7. Administration of aromatase inhibitor MPV-2213ad to blue fox vixens (Vulpes lagopus) as a model for contraception in female dogs.
Lindh L; Lindeberg H; Banting A; Banting S; Sainmaa S; Beasley S; Korhonen HT; Peltoniemi OAT
Theriogenology; 2020 Aug; 152():53-63. PubMed ID: 32380275
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
J Clin Endocrinol Metab; 1993 Aug; 77(2):324-31. PubMed ID: 8345035
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.
Schultze-Mosgau MH; Waellnitz K; Nave R; Klein S; Kraetzschmar J; Rautenberg T; Schmitz H; Rohde B
Hum Reprod; 2016 Aug; 31(8):1713-22. PubMed ID: 27390369
[TBL] [Abstract][Full Text] [Related]
10. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings.
Tominaga T; Suzuki T
Anticancer Res; 2003; 23(4):3533-42. PubMed ID: 12926103
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose anastrozole in healthy, premenopausal female volunteers.
Tredway DR; Buraglio M; Hemsey G; Denton G
Fertil Steril; 2004 Dec; 82(6):1587-93. PubMed ID: 15589864
[TBL] [Abstract][Full Text] [Related]
12. Estrogen suppression in males: metabolic effects.
Mauras N; O'Brien KO; Klein KO; Hayes V
J Clin Endocrinol Metab; 2000 Jul; 85(7):2370-7. PubMed ID: 10902781
[TBL] [Abstract][Full Text] [Related]
13. Differential regulation of gonadotropin secretion by testosterone in the human male: absence of a negative feedback effect of testosterone on follicle-stimulating hormone secretion.
Hayes FJ; DeCruz S; Seminara SB; Boepple PA; Crowley WF
J Clin Endocrinol Metab; 2001 Jan; 86(1):53-8. PubMed ID: 11231978
[TBL] [Abstract][Full Text] [Related]
14. Anastrozole--a new generation in aromatase inhibition: clinical pharmacology.
Dowsett M; Lønning PE
Oncology; 1997; 54 Suppl 2():11-4. PubMed ID: 9394854
[TBL] [Abstract][Full Text] [Related]
15. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
16. The relevance of preclinical models to the treatment of postmenopausal breast cancer.
Dukes M
Oncology; 1997; 54 Suppl 2():6-10. PubMed ID: 9394853
[TBL] [Abstract][Full Text] [Related]
17. Letrozole-induced polycystic ovaries in the rat: a new model for cystic ovarian disease.
Kafali H; Iriadam M; Ozardali I; Demir N
Arch Med Res; 2004; 35(2):103-8. PubMed ID: 15010188
[TBL] [Abstract][Full Text] [Related]
18. Aromatization mediates testosterone's short-term feedback restraint of 24-hour endogenously driven and acute exogenous gonadotropin-releasing hormone-stimulated luteinizing hormone and follicle-stimulating hormone secretion in young men.
Schnorr JA; Bray MJ; Veldhuis JD
J Clin Endocrinol Metab; 2001 Jun; 86(6):2600-6. PubMed ID: 11397860
[TBL] [Abstract][Full Text] [Related]
19. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
20. Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia.
Loves S; de Jong J; van Sorge A; Telting D; Tack CJ; Hermus A; Westerterp K; de Boer H
Eur J Endocrinol; 2013 Nov; 169(5):705-14. PubMed ID: 23949882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
